Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Fuji
Deloitte
Dow
Colorcon
Teva
Queensland Health
Moodys
Cantor Fitzgerald
AstraZeneca

Generated: February 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,677,358

« Back to Dashboard

Summary for Patent: 6,677,358
Title: NIDDM regimen
Abstract:The present invention discloses a regimen for the treatment of type 2 diabetes, in which the endogenous secretion of insulin is stimulated in connection with meals, by administering a short-acting, oral hypoglycemic agent. Also, the present invention discloses a method of achieving improvement in glycemic control by combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone.
Inventor(s): Muller; Peter Gi.o slashed.rtz (Princeton Junction, NJ)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:09/459,526
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use; Device;

Drugs Protected by US Patent 6,677,358

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,677,358

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark0694/97Jun 13, 1997

International Patents Family Members for US Patent 6,677,358

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 201139 ➤ Try a Free Trial
Australia 7906898 ➤ Try a Free Trial
Germany 69800806 ➤ Try a Free Trial
Denmark 1011673 ➤ Try a Free Trial
European Patent Office 1011673 ➤ Try a Free Trial
European Patent Office 1097710 ➤ Try a Free Trial
Spain 2159184 ➤ Try a Free Trial
Greece 3036078 ➤ Try a Free Trial
Hong Kong 1030872 ➤ Try a Free Trial
Japan 2002500677 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Baxter
McKesson
Accenture
Fuji
Fish and Richardson
Julphar
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot